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HE EPSTEIN-BARR VIRUS (EBV) is associated with
a variety of lymphoid and epithelial neoplasms, including Burkitt's lymphoma (BL),'.' Hodgkin's disease (HD),3 posttransplant lymphoproliferative disorders (FTLD),"' and undifferentiated nasopharyngeal carcinomas (NPC).'36 In these tumors, monoclonal viral genomes have been identified in virtually all tumor cells indicating that EBV infection takes place early in the neoplastic process and suggesting an important role for the virus in tumor d e~e l o p m e n t .~~~-~ The nature of the contribution of EBV, however, remains uncertain. Studies of EBV gene expression in virus carrying cell lines and in human tumor biopsy specimens have identified three distinct forms of virus latency. Lymphoblastoid cell lines (LCLs), generated by in vitro immortalization of B lymphocytes with EBV, express an array of virus-encoded proteins including six nuclear antigens (EBNA1, 2, 3A, 3B, 3C, -leader protein [LP] ) and three latent membrane proteins (LMP1, 2A, 2B)? The small EBV-encoded nonpolyadenylated nuclear RNAs (EBER1 and 2) are also expressed at high copy numbers in these cell^.'^'^ In LCLs, all six EBNAs are generated by differential splicing of a single large primary RNA transcript originating from one of two promoters located at the left end of the linear viral genome in the BarnHI C or BarnHI gen 3 (LFA-3) and intercellular adhesion molecule-l (ICAM-l), which are important for the adhesion of cytotoxic T cells." Furthermore, certain HLA class I alleles are selectively downregulated in BL ~ells.'*~'~ Recent research points to the restricted expression of EBV genes as the main reason for the inability of the immune system to control BL
The EBV-specific cytotoxic T lymphocyte (CTL) response seems to be directed mainly against epitopes of the EBNA3 family of proteins that are not expressed in BL, while CTLs directed against the EBNAl protein have not yet been observed.26s27
Previous studies of EBV gene expression in BL have been carried out using mainly cell lines and employing techniques relying on the extraction of proteins or RNA from cells or tissue^.^"'^ These methods are of limited sensitivity and expression of viral proteins other than EBNAl in a small proportion of BL cells may not be detected. Therefore, we have used sensitive immunohistologic techniques to re-examine EBV gene expression in BL biopsy specimens.
MATERIALS AND METHODS

Tissues.
Formalin-fixed and paraffin-embedded biopsy specimens from 17 cases were included in this study. All cases were from areas in Africa where Burkitt's lymphoma is endemic (8 from Uganda, 9 from Malawi) and collected between 1972 and 1994. All biopsy specimens were from children, aged between 2 and 16 years. The clinicopathologic data are summarized in Immunohistology. The MoAb, Ber-H2, directed against the CD30 lymphocyte activation antigen and the bcl2-specific MoAb, 124, were obtained from Dako. For the detection of LMPI, the MoAbs CSI, CS2, CS3, and CS4 were used either alone or in a commercially available combination (Dako).** In addition, a newly produced murine IgGl subclass LMPl-specific MoAb, LMP024, was used. This antibody was generated by immunizing balbk mice with purified plasma membranes from LMPI-expressing insect cells that were infected with a recombinant LMPl baculovirus. The recombinant baculovirus was a kind gift of Dr F. Grasser (Universitatskliniken des Saarlandes, Homburg, Germany) and has been described p r e v i o~s l y .~~ Spleen cells from an immunized mouse were fused with the nonsecreting myeloma fusion partner, Sp2/0-Ag14; several hybridomas were found to produce antibodies reactive with LMPl in fixed cell smears and in Western blotting assays. The LMP024 clone was selected for use in this study because of its strong and specific reactivity in immunohistochemical staining of paraffin-embedded tissues. The MoAb, PE2, was used for the detection of the EBNA2 protein," and the BZ1 MoAb was employed for the detection of the BZLFl trans-activator pr~tein.~" All MoAbs were applied to paraffin-sections following antigen retrieval as de~cribed.~' In brief, dewaxed and rehydrated paraffin sections were subjected to microwave irradiation in 1 dm3 of 0.01 m o a citrate buffer for 40 minutes at 750 W. Sections were then stained using the alkaline phosphatase anti-alkaline phosphatase (APAAP) method as described. 3' In situ hybridization. The plasmids pBSJJJl and pBSJJJ2 harboring inserts specific for EBERl and EBER2, respectively, and the plasmid pBSW containing the BamHI W fragment of the EBV genome were employed in this study.32 Following digestion with suitable restriction enzymes, single stranded RNA probes were generated from these plasmids in sense and antisense direction using T3 and T7 RNA polymerases (Gibco-BRL, Paisley, UK) and 3%-dUTP (> 1000 Cihmol, Amersham, Little Chalfont, UK) as described.
The antisense probes derived from the plasmids pBSJJJl and pBSJJJ2 were mixed to increase sensitivity, and the corresponding sense probes were also mixed. In situ hybridization was performed overnight as described"," using a hybridization mixture containing SO% deionized formamide, 2 X SSC (0.3 m o m NaCI, 0.03 m o m sodium citrate, pH 7.6), 10% dextran sulphate, 10 mmoUL dithiothreitol (DTT), 0.2 mglmL yeast tRNA, and lo5 cpm of labeled probe per slide. After hybridization, slides were washed for at least 4 hours in 50% deionized formamide, 1 X SSC, 10 mmom DTT at 52°C rinsed in 0.1 X SSC, and dipped in a 1.2 dilution of Ilford G5 emulsion. Slides were exposed at 4°C for 3 to I O days, developed, fixed, and counterstained.
Controls. Paraffin sections of a tonsil from a patient with acute infectious mononucleosis (IM) were used as positive control in all experiments. EBER in situ hybridization showed numerous EBVinfected lymphoid blasts in extrafollicular areas as described previously. Preliminary experiments with the CSI, CS2, CS3, and CS4 MoAbs on sections from an IM tonsil showed large numbers of LMPl expressing lymphoid blasts with each individual MoAb as seen with the CSI-4 mixture. However, the CS3 and particularly the CS4 MoAbs produced a strong staining of many nuclei and a cytoplasmic labeling of endothelial cells in addition to the specific staining. This has been occasionally observed previously with the CS 1-4 mixture." Serial dilution of the CS3 and CS4 MoAbs showed that at tissue culture supernatant dilutions of about 1 :500, the nuclear staining had disappeared almost completely, while the specific staining of EBV-infected lymphoid blasts was still clearly visible. A weak staining of endothelial cells remained, but this did not interfere with the interpretation of results. The CS1, CS2, and LMP024 MoAbs did not show any background staining at dilutions of 1:50.
RESULTS
EBV status of tumors. In situ hybridization with the EBER1-and EBER2-specific probes showed the presence of EBV in virtually all tumor cells of all 17 BL cases (Fig  1 and Table 1 ).
M P 1 expression. Immunohistology with the CS1-4 mixture of MoAbs showed labeling of a substantial number of tumor cells in one case (Fig 2A and case no. 7 in Table  I ). Positive cells tended to show focal aggregation. Because of the focal distribution of these cells the proportion of labeled tumor cells was difficult to assess. While in some areas up to 40 CSl-4-positive cells were found per high power field (Fig 2A) , the vast majority of tumor cells was unlabeled. The proportion of CS1-4-positive cells was estimated to be less than 1 % of the total tumor cell population. Another case (case 17 in Table l) , displayed very few cells labeled with the CS1-4 MoAbs, again representing well under 1% of all tumor cells. To assess the specificity of this staining result, the CS 1 , CS2, CS3, CS4, and LMPO24 MoAbs were applied separately to these cases. All five antibodies showed the same staining pattern in both cases confirming the specificity of the staining result (Fig 2B) . While the majority of LMPlexpressing cells shared the morphologic features of BL tu- tumor cells in three cases (Fig 3A and B and Table 1 ). The largest number of EBNA2-positive cells was observed in case no. 3. In this case, labeled cells showed a focal distribution pattern and staining was often weak, making assessment of the number of EBNA2-expressing cells difficult. However, the vast majority of tumor cells did not show EBNAZ specific staining and thus the overall proportion of stained cells was small (< 1 %). Only very few scattered cells labeled with the PE2 mAB were seen in the other 2 cases.
Notably, these 3 cases did not show any LMP1-expressing cells (Table 1) . Most PE2-positive cells shared the morphology of tumor cells, but a few isolated cells with a more immunoblast-like appearance were noticed in 1 case. To ascertain the specificity of this staining, in situ hybridization with RNA probes derived from the plasmid pBSW was performed on these 3 cases. This probe detects mRNA transcripts derived from the BmHI W fragment of the viral genome, which are transcribed in type III latency, and are part of the primary transcript encoding for EBNA2, as well as the other EBNAs. Scattered cells expressing this RNA were detected in one of the three cases with PE2-positive cells (not shown). BZLFl expression. Using the BZLF1-specific MoAb, BZ1, nuclear staining of isolated tumor cells was observed in 6 BL cases (Fig 4 and Table 1 ). Invariably, these cells showed the morphologic features of BL tumor cells (Fig 4) .
CD30 and bc12 expression. Staining with the MoAb Ber-H2 of 16 cases showed a few CD30-positive lymphoid cells in 1 case (case no. 5 in Table l) , and this case also displayed some EBNA2-positive tumor cells. However, the CD30-expressing cells had the morphologic features of lymphoid blasts and were located at the edge of the tumor and thus probably represented reactive lymphoid cells rather than transformed tumor cells. The 5 cases containing LMPl or EBNA2 expressing cells were stained with a bcl2-specific MoAb, 124. In all 5 cases, bc12 expression was restricted to small lymphoid cells. No bc12 expression in tumor cells was observed. For personal use only. on May 31, 2017 . by guest www.bloodjournal.org From
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DISCUSSION
In this study of 17 EBV-positive endemic BL cases, variable but small numbers of LMP1-expressing cells were observed in 2 cases and isolated EBNAZpositive tumor cells were detectable in 3 other cases. In the remaining 12 cases, EBV latent gene expression was restricted to the EBERs, consistent with a tight type I latency. A few isolated BL cells expressing the BZLFl trans-activator protein of EBV were observed in 6 cases. This protein induces the switch from latent to replicative EBV infection. Thus, expression of the BZLFl protein suggests that a small minority of BL cells in some cases may enter into the lytic cycle. This is in keeping with the occurrence of occasional virus-producing cells in some BL cell line^^.'^ and with the recent demonstration using Southern blot hybridization of replicating EBV DNA in some BL biopsy specimens.34
The detection of some EBNA2-and LMP1-positive cells in a proportion of endemic BL cases was unexpected in the light of previous studies consistently demonstrating a type I latency in BL.I7-l9 However, these studies have employed methods based on the extraction of proteins and nucleic acids, such as Western or Northern blotting. While these techniques allow the analysis of EBV gene expression in the majority cell population, they may not be sufficiently sensitive to detect different expression patterns in small fractions of the total cell population. Also, these studies have examined mainly early passage BL cell lines and thus the number of BL biopsy specimens analyzed for EBV gene expression reported in the literature is very small.
Several control experiments were performed to assess the specificity of our immunostaining results. The 2 cases with LMP1-positive cells as detected using the CS1-4 mixture of MoAbs were examined using these four MoAbs separately and also with a newly generated LMP1-specific MoAb, LMPO24. Identical staining patterns were obtained in both cases with all five MoAbs. In 1 of the 3 cases displaying scattered cells labeled with the EBNA2-specific MoAb, small numbers expressing RNAs derived from the BurnHI W fragment of the EBV genome were identified. These transcripts are part of the EBNA2 mRNA expressed in Lat Thus, these control experiments provide additional evidence for the specificity of our immunostaining results.
Expression of LMPl may occur during lytic infection in B cells. 35 However, in our cases, there was no correlation between LMPl and BZLFl expression (Table 1) . A few BZLF1-positive BL cells were seen in the case showing the most LMP1-positive cells (case no. 7, Table l), but these were infrequent in comparison to the LMP1-positive cells and they also showed a different pattern of distribution. Thus, the presence of LMP1-positive cells in these two biopsy specimens clearly reflects the expression of LMPl in the context of latent infection.
The expression of LMPl has been demonstrated previously in 3 of 11 EBV-positive acquired immunodeficiency syndrome (AIDS) related BL cases.36 Thus, the detection of LMP1-positive cells in our cases no. 7 and 17 (Table 1) raises the question as to the possibility of human immunodeficiency virus (W) infection in these patients. However, the biopsy specimen from case no. 7 was obtained in 1982 before the outbreak of the AIDS epidemic. This tumor had developed in an ovary of a young girl. In case no. 17, the tumor had developed in the mandible of a 12-year old girl in 1994. Therefore, both cases would seem to represent typical examples of endemic BL. A recent autopsy study from Cote d'Ivoire has also concluded that BL is not a common A I D Sassociated complication in Africa, particularly in children. 37 Thus, while we cannot definitely rule out this possibility, it seems very unlikely that these cases represent AIDS-related lymphomas.
In 12 of our endemic BL cases, the immunohistologic results were in keeping with a tight Lat I form of EBV infection as described in previous ~tudies. In vitro, some BL cell lines show a spontaneous phenotypic drift from Lat I to Lat III.I7 Thus, the detection of LMPl or EBNA2 in BL cells suggests that such a drift may also occur in vivo. Alternatively, it is possible that the BL cells expressing LMPl or EBNA2 represent earlier stages in tumor development before the establishment of a tight Lat I. While the first possibility appears more likely, it is, at present, not possible to clarify this issue with certainty. A step in this direction would be a more detailed phenotypic characterization of BL cells expressing EBNA2 or LMPl to see if the phenotypic changes associated with the drift from Lat I to Lat 111 in vitro are reflected in these tumor cells in vivo. Our preliminary analysis suggests that CD30, which is expressed in type 111 but not in type I BL cell lines,I7 is not upregulated in EBNA2 or LMPl expressing BL cells in vivo. Similarly, expression of the bcZ2 oncoprotein was not observed in these BL cases. This is surprising in view of the recently demonstrated ability of LMPl to upregulate bcZ2 expression in BL cell lines.39 However, a few EBNA2-or LMP1-expressing cells were noticed that displayed an immunoblast-like morphology, and this problem will have to be addressed in more detail using frozen biopsies that will allow a broader range of antigens to be analyzed.
The phenotypic analysis of LMPl or EBNA2 expressing BL cells is also important with respect to the understanding of the immunologic control of BL in vivo. EBV-positive endemic BL develops in the face of an EBV-specific immunity apparently sufficient to prevent the outgrowth of conventional EBV transformed B cells, ie, immunoblastic lymphomas with a type 111 latency. This raises the question as to which mechanisms are responsible for allowing BL cells to evade EBV-specific CTL surveillance. Previous studies have variably implicated the characteristically low expression of adhesion molecules in BL, the downregulation of HLA class I expression, or the absence of those EBV proteins that provide the immunogenic target epitopes, eg, EBNA3B and EBNA3C.2"27 Recent evidence seems to suggest that the most important factor is the restriction of EBV protein expression to EBNA1, which is the only EBV-encoded protein against which T-cell immunity has, as yet, not been d e m o n~t r a t e d .~~-~~ Thus, the absence of BL cells dispIaying a type I1 or type I11 EBV latency from most BL biopsies and the scarcity of such cells in those cases where they are detectable could be explained by the rapid elimination of these cells by EBV-specific CTLs. This could also explain that in those cases showing EBNA2-positive cells, LMPl expression was not observed. During the switch from Lat I to Lat 111, EBNA2 expression precedes LMPl expres~i o n . '~ Thus, it seems possible that EBNA2-expressing BL cells are eliminated by CTLs before the EBNA2-induced upregulation of LMPl expression can occur. If the relatively small number of T cells detected in BL biopsies is sufficient to mediate such an effect remains to be established. In summary, this is the first demonstration of EBV latent proteins other than EBNAl in tumor cells of endemic BL. The expression of EBNAZ in some tumor cells suggests a drift towards Lat 111, as seen in some BL cell lines in vitro. In other cases, expression of LMPl has been observed without detectable EBNA2 expression, raising the possibility that BL cells may, under certain conditions, sustain Lat 11. These possibilities will have to be addressed at the transcriptional level in future studies. Our observations demonstrate that in virus-associated human tumors. individual tumor cells may sustain a form of EBV latency that is different from the pattern prevailing in the majority cell population. Thus, the operational definition of different forms of EBV latency is not easily applicable to human tumors in vivo.
